A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia

Mark R. Litzow; Sandra Lee; John M. Bennett; Gordon W. Dewald; Robert E. Gallagher; Vibha Jain; Elisabeth M. Paietta; Janis Racevskis; Steven R. Rousey; Joseph J. Mazza; Martin S. Tallman

A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia

Mark R. Litzow^*, Sandra Lee, John M. Bennett, Gordon W. Dewald, Robert E. Gallagher, Vibha Jain, Elisabeth M. Paietta, Janis Racevskis, Steven R. Rousey, Joseph J. Mazza, Martin S. Tallman

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.

Original language	English (US)
Pages (from-to)	1105-1108
Number of pages	4
Journal	Haematologica
Volume	91
Issue number	8
State	Published - Aug 2006

Keywords

Acute lymphoblastic leukemia
Arsenic trioxide
Relapse

ASJC Scopus subject areas

Hematology

Cite this

@article{6c57689cdf89460dbe10c88c3c17c808,

title = "A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia",

abstract = "We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.",

keywords = "Acute lymphoblastic leukemia, Arsenic trioxide, Relapse",

author = "Litzow, {Mark R.} and Sandra Lee and Bennett, {John M.} and Dewald, {Gordon W.} and Gallagher, {Robert E.} and Vibha Jain and Paietta, {Elisabeth M.} and Janis Racevskis and Rousey, {Steven R.} and Mazza, {Joseph J.} and Tallman, {Martin S.}",

year = "2006",

month = aug,

language = "English (US)",

volume = "91",

pages = "1105--1108",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "8",

}

TY - JOUR

T1 - A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia

AU - Litzow, Mark R.

AU - Lee, Sandra

AU - Bennett, John M.

AU - Dewald, Gordon W.

AU - Gallagher, Robert E.

AU - Jain, Vibha

AU - Paietta, Elisabeth M.

AU - Racevskis, Janis

AU - Rousey, Steven R.

AU - Mazza, Joseph J.

AU - Tallman, Martin S.

PY - 2006/8

Y1 - 2006/8

N2 - We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.

AB - We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.

KW - Acute lymphoblastic leukemia

KW - Arsenic trioxide

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=33746979218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746979218&partnerID=8YFLogxK

M3 - Article

C2 - 16870552

AN - SCOPUS:33746979218

SN - 0390-6078

VL - 91

SP - 1105

EP - 1108

JO - Haematologica

JF - Haematologica

IS - 8

ER -

A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this